With Baxter split looming, biotech Baxalta finds a new home for corporate HQ

Baxter's ($BAX) big biotech spinoff Baxalta has found a corporate home. The company has leased a sprawling 260,000-square-foot facility in Bannockburn, IL, not far from its original HQ in northern Illinois. With a split looming this summer, Baxalta will spring into existence with $6 billion in revenue and a substantial R&D operation. The company recently announced plans to set up its research shop in the big Cambridge/Boston hub, drawing in 400 investigators from Europe and California. Ludwig Hantson will be the new CEO. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.